Skip to content

Diltiazem

    DEA Class; Rx

    Common Brand Names; Cardizem, Cardizem CD, Cardizem LA, Cartia XT, Dilacor, Dilacor XR, Dilatrate, Diltazem, Diltazem CD, Dilt-CD, Diltia XT, Diltiaz, Diltiaz CD, Diltiaz SR, Diltiazem CD, Diltiazem SR, Dilzem, Taztia XT, Tiazac

    • Antidysrhythmics, IV; 
    • Calcium Channel Blockers; 
    • Calcium Channel Blockers, Non-dihydropyridine

    Oral and IV, benzothiazepine calcium-channel blocker; primarily used for angina, HTN, PST, and ventricular rate control in AFIB; slows AV conduction; vasodilatory properties; less negative inotropic effects than verapamil or nifedipine.

    Indicated for the treatment of hypertension.

    For the treatment of chronic stable angina.
    For the treatment of variant angina (Prinzmetal’s angina).
    For the treatment of paroxysmal supraventricular tachycardia (PSVT) or control of ventricular rate in atrial flutter or atrial fibrillation.
    For the relief of ongoing ischemia in patients with unstable angina or after acute non-ST-segment elevation myocardial infarction in the absence of congestive heart failure, pulmonary congestion, left ventricular dysfunction, or AV block, when beta-blockers are ineffective or contraindicated.
    For the treatment of idiopathic dilated cardiomyopathy.
    For the treatment of proteinuria associated with diabetic nephropathy.
    For the treatment of anal fissures.
    For the treatment of pulmonary hypertension.

     

    Hypersensitivity

    Wolff-Parkinson-White syndrome, Lown-Ganong-Levine syndrome, symptomatic severe hypotension (systolic BP <90 mm Hg), sick sinus syndrome (if no pacemaker), 2°/3° (if no pacemaker); heart block

    PO: Acute MI and pulmonary congestion

    IV: Use in newborns (because of benzyl alcohol), concomitant beta-blocker therapy, cardiogenic shock, ventricular tachycardia (must determine whether origin is supraventricular or ventricular)

    • Edema (2-15%)
    • Headache (5-12%)
    • Dizziness (3-10%)
    • AV block (2-8%)
    • Peripheral edema (2-8%)
    • Bradyarrhythmia (2-6%)
    • Headache (1-5%)
    • Hypotension (2-4%)
    • Nausea (3%)
    • Vomiting (2%)
    • Vasodilation (2-3%)
    • Extrasystoles (2%)
    • Flushing (1-2%)
    • Drug-induced gingival hyperplasia (<2%)
    • Myalgia (2%)
    • Diarrhea (1-2%)
    • Constipation (2-4%)
    • Bronchitis (1-4%)
    • Sinus congestion (1-2%)
    • Dyspnea (1-6%)
    • Congestion (1-2%)
    • Increased Alkaline phosphatase as well as ALT and AST
    • CHF
    • Thrombocytopenia
    • Toxic epidermal necrolysis
    • Hemolytic anemia
    • Photosensitivity
    • Extrapyramidal symptoms
    • Syncope

    May cause abnormally slow heart rates or second- or third-degree AV block’ patients with sick sinus syndrome are at increased risk of bradycardia (risk increases with agents known to slow cardiac conduction

    Stevens-Johnson syndrome, toxic epidermal necrolusis, erythema multiforme and/or exfoliative dermatitis reported

    Significant elevations in liver enzymes such as alkaline phosphatase, LDH, AST (SGOT), ALT (SGPT) and signs of acute hepatic injury reported; reversible upon discontinuation of drug therapy

    Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin observed; elevations were usually resolved even with continued diltiazem treatment

    Symptomatic hypotension with or without syncope reported

    Peripheral edema occurs within 2-3 weeks of starting therapy

    Use with caution in hypertrophic obstructive cariomyopathy, hepatic/renal impairment, left ventricular dysfunction

    Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction; sinus bradycardia resulting in hospitalization reported with concurrent use of clonidine and other agents that slow cardiac conduction

    May increase the risk of adverse cardiac events in patients with heart failure due to negative inotropic effects (risk directly related to the severity of baseline HF)

    Pregnancy category: C

    Lactation: Drug enters breast milk; because of risk for serious adverse reactions in nursing infants from diltiazem, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

    Adults

    360 mg/day PO for diltiazem tablets and twice-daily extended-release capsules (e.g., Cardizem, Cardizem SR); 540 mg/day PO for hypertension for once-daily extended-release formulations (e.g., Dilacor-XR capsules, Tiazac capsules, Cardizem CD, Cardizem LA tablets).

    Geriatric

    360 mg/day PO for diltiazem tablets and twice-daily extended-release capsules (e.g., Cardizem, Cardizem SR); 540 mg/day PO for hypertension for once-daily extended-release formulations (e.g., Dilacor-XR capsules, Tiazac capsules, Cardizem CD, Cardizem LA tablets).

    Adolescents

    Safety and efficacy have not been established; doses of 6 mg/kg (up to 360 mg) per day PO have been used off-label for hypertension.

    Children

    Safety and efficacy have not been established; doses of 6 mg/kg (up to 360 mg) per day PO have been used off-label for hypertension.

    Diltiazem hydrochloride

    capsule/tablet, extended release

    • 120mg
    • 180mg
    • 240mg
    • 300mg
    • 360mg
    • 420mg

    injectable solution

    • 5mg/mL

    powder for injection

    • 100mg

    tablet

    • 30mg
    • 60mg
    • 90mg
    • 120mg